<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05108974</url>
  </required_header>
  <id_info>
    <org_study_id>UMN-1506M74642</org_study_id>
    <secondary_id>R01AA024123</secondary_id>
    <nct_id>NCT05108974</nct_id>
  </id_info>
  <brief_title>Choline Supplementation as a Neurodevelopmental Intervention in Fetal Alcohol Spectrum Disorders Study</brief_title>
  <acronym>CHOLINE4</acronym>
  <official_title>Choline Supplementation as a Neurodevelopmental Intervention in Fetal Alcohol Spectrum Disorders Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeff Wozniak</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind controlled trial of choline supplementation in children&#xD;
      with Fetal Alcohol Spectrum Disorders (FASD). The study is comparing two administration&#xD;
      durations (3 months vs. 6 months) of choline. The primary outcome measures are cognitive&#xD;
      measures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project is the fourth in a series of randomized, double-blind controlled trials of&#xD;
      choline bitartrate in children ages 2-5 (under 6) years with prenatal alcohol exposure.&#xD;
      Pre-clinical data suggests that choline may attenuate the cognitive deficits caused by&#xD;
      prenatal alcohol exposure (especially memory deficits). This study will evaluate the effects&#xD;
      of daily choline supplementation in two dosing regimens (3 months choline vs. 6 months&#xD;
      choline). Outcome measures include an elicited imitation memory paradigm, IQ measures, and&#xD;
      measures of memory and executive functioning, and behavior.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Elicited Imitation Memory Task (EI)</measure>
    <time_frame>Change from baseline to 9 months</time_frame>
    <description>Elicited Imitation short-delay memory measure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stanford-Binet Intelligence Test (SB-5)</measure>
    <time_frame>Change from baseline to 9 months</time_frame>
    <description>Stanford Binet Intelligence Test - 5th Edition</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minnesota Executive Function Scale (MEFS)</measure>
    <time_frame>Change from baseline to 9 months</time_frame>
    <description>Minnesota Executive Function Scale - Early Childhood Version</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NIH Toolbox Flanker Test</measure>
    <time_frame>Change from baseline to 9 months</time_frame>
    <description>NIH Toolbox Flanker Inhibitory and Control Test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NIH Toolbox Picture Sequence Memory Test</measure>
    <time_frame>Change from baseline to 9 months</time_frame>
    <description>NIH Toolbox Picture Sequence Memory Test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Child Behavior Checklist (CBCL)</measure>
    <time_frame>Change from baseline to 9 months</time_frame>
    <description>Child Behavior Checklist - Parent Report Version</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Fetal Alcohol Spectrum Disorders</condition>
  <arm_group>
    <arm_group_label>3 months choline bitartrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Over the 9-month study, participants will receive a total of 3 months of choline bitartrate (19 mg/kg) and a total of 6 months of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 months choline bitartrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Over the 9-month study, participants will receive a total of 6 months of choline bitartrate (19 mg/kg) and a total of 3 months of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Choline Bitartrate</intervention_name>
    <description>Powdered drink mix for daily consumption</description>
    <arm_group_label>3 months choline bitartrate</arm_group_label>
    <arm_group_label>6 months choline bitartrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages 2.5 years to 5 years old (&lt;6 years of age) at enrollment&#xD;
&#xD;
          -  Prenatal alcohol exposure&#xD;
&#xD;
          -  Available parent or legal guardian capable of giving informed consent for&#xD;
             participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of a neurological condition (ex. epilepsy, traumatic brain injury)&#xD;
&#xD;
          -  History of a medical condition known to affect brain function&#xD;
&#xD;
          -  Other neurodevelopmental disorder (ex. autism, Down syndrome)&#xD;
&#xD;
          -  History of very low birthweight (&lt;1500 grams)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Months</minimum_age>
    <maximum_age>72 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jeffrey R Wozniak, Ph.D.</last_name>
    <phone>612-598-0041</phone>
    <email>jwozniak@umn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael K Georgieff, M.D.</last_name>
    <phone>712-626-2971</phone>
    <email>georg001@umn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey R Wozniak, Ph.D.</last_name>
      <phone>612-273-9741</phone>
      <email>jwozniak@umn.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>October 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Minnesota</investigator_affiliation>
    <investigator_full_name>Jeff Wozniak</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Alcohol Spectrum Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

